CCR2
C-C chemokine receptor type 2
As of the edition of 20 October 2026, CCR2 (C-C chemokine receptor type 2, UniProt P41597) has 14 drugs tested at it and 12 companies on the list, 11 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P41597
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 7
- Disease areas
- Hormones; Digestive system; Urinary and reproductive; Pregnancy and women's health; Cancer; Nervous system; Nutrition and metabolism; Immune system
- Registered trials of its drugs
- 62
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 5 |
| Stopped | 8 |
| Total | 14 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Cenicriviroc | Stopped | Phase 3 | none listed |
| AZD2423 | Went quiet | Phase 2 | none listed |
| BMS-813160 | Stopped | Phase 2 | none listed |
| Ilacirnon | Stopped | Phase 2 | none listed |
| Plozalizumab | Stopped | Phase 2 | none listed |
| PF-04634817 | Stopped | Phase 2 | none listed |
| PF-4136309 | Stopped | Phase 2 | none listed |
| JNJ-41443532 | Went quiet | Phase 2 | none listed |
| BMS-741672 | Went quiet | Phase 2 | none listed |
| CCX872-B | Went quiet | Phase 2 | none listed |
| CNTX-6970 | Active | Phase 2 | none listed |
| MK-0812 | Stopped | Phase 2 | none listed |
12 of 14 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 11 |
| Engaged | 1 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| Novartis | Route A |
| Pfizer | Route A |
| Merck & Co. | Route A |
The other 9 companies at CCR2
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at CCR2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.